ERBB2 and breast carcinoma: Moreover, NECL2 and NECL4 can interact with PTPN13 to inhibit the ERBB2/ERBB3 pathway in colorectal cancer (Caco-2), breast cancer (MCF7), and human embryonic kidney (HEK293) cells [77,78].